Sessions
DEVELOPING A COMMERCIALLY ROBUST SUPPLY CHAIN ACROSS THE EUROPEAN CONTINENT
REVOLUTIONISING VIRAL VECTOR DEVELOPMENT IN EUROPE
EUROPEAN EXPANSION; MANUFACTURING HIGH QUALITY, LOW COST & LARGE VOLUME CELL & GENE THERAPIES
EXPLORING THE SHIFT TOWARDS POINT OF CARE AUTOMATION & DECENTRALISED MANUFACTURING
EUROPEAN SCALABILITY CONSIDERATIONS TO INDUSTRIALISE EARLY ACADEMIC TRANSLATION
DEVELOPING A COMMERCIALLY ROBUST SUPPLY CHAIN ACROSS THE EUROPEAN CONTINENT
SPONSORED BY
15:30 – CHAIR INTRODUCTION
Chair: Stephen Sullivan, Programme Manager & International Liaison Officer, GAiT
15:35 – CASE STUDY
Speaker: Julia Sable, Director CMC Project Management, Tmunity
15:50 – CASE STUDY
Speaker:
16:05 – CASE STUDY: HOW THE EUROPEAN QUALIFIED PERSON & BATCH RELEASE IS IMPACTING CELL THERAPY DISTRIBUTION
Speaker: Andrea Zobel, Senior Director, Personalized Supply Chain, World Courier
16:20 – CASE STUDY: FRESH TO FROZEN & INTEGRATION: DE-RISKING THE CELL THEARPY SUPPLY CHAIN
Ludwig Camusot, Chief Corporate Development Officer, Cell-Matters
16:35 – PANEL DISCUSSION
Speakers:
Ludwig Camusot, Chief Corporate Development Officer, Cell-Matters
Julia Sable, Director CMC Project Management, Tmunity
Andrea Zobel, Senior Director, Personalized Supply Chain, World Courier
Speakers
